Alaunos Therapeutics (TCRT) Net Cash Flow (2009 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Net Cash Flow came in at -$1.0 million in Q1 2026, down 33.55% YoY from -$1.6 million in Q1 2025, and down 86.44% on a QoQ basis from -$553000.0 in Q4 2025.
Alaunos Therapeutics (TCRT) Net Cash Flow (2009 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 18 years of Net Cash Flow data on file, last reported at -$1.0 million in Q1 2026.
- Quarterly Net Cash Flow fell 33.55% year-over-year to -$1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.1 million (up 18.22% YoY) and the FY2025 annual result came in at $294000.0, up 105.91% from the prior year.
- Net Cash Flow eased to -$1.0 million in Q1 2026, from -$553000.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $1.3 million in Q4 2022 to a low of -$19.1 million in Q2 2023.
- A 5-year average of -$4.6 million and a median of -$1.7 million in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow soared 107.98% — and 2023, when it plunged 570.18%.
- Tracing TCRT's Net Cash Flow over 5 years: stood at $1.3 million in 2022, then sank by 570.18% to -$5.9 million in 2023, then jumped by 89.94% to -$592000.0 in 2024, then advanced by 6.59% to -$553000.0 in 2025, then plunged by 86.44% to -$1.0 million in 2026.
- The last three Net Cash Flow figures came in at -$1.0 million (Q1 2026), -$553000.0 (Q4 2025), and -$844000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | -300,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.03 Mn |
| Mar 31, 2026 | -1.03 Mn |
| Dec 31, 2025 | -553,000.00 |
| Dec 31, 2025 | -553,000.00 |
| Sep 30, 2025 | -844,000.00 |
| Sep 30, 2025 | -844,000.00 |
| Jun 30, 2025 | -701,000.00 |
| Jun 30, 2025 | -701,000.00 |
| Mar 31, 2025 | -772,000.00 |
| Mar 31, 2025 | -772,000.00 |
| Dec 31, 2024 | -592,000.00 |
| Dec 31, 2024 | -592,000.00 |
| Sep 30, 2024 | -781,000.00 |
| Sep 30, 2024 | -781,000.00 |
| Jun 30, 2024 | -1.68 Mn |
| Jun 30, 2024 | -1.68 Mn |
| Mar 31, 2024 | -1.92 Mn |
| Mar 31, 2024 | -1.92 Mn |
| Dec 31, 2023 | -5.88 Mn |
| Dec 31, 2023 | -5.88 Mn |